OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Patrick Evershed
Manager of New Star Select Opportunities Fund

FTSE 100 5,250 (5,500). I fear the very large Government budget deficits, record levels of personal indebtedness and dangerously large trade deficits in the USA and UK will undermine the prolonged period of economic growth and high profit margins.

If the rate of economic growth does slow and profit margins come under pressure at least some of the exceptionally highly geared private equity funds could find themselves in trouble.

Top share Oxford BioMedica could complete value enhancing deals during the year. The first could be for its lead cancer drug TroVax. The second could be for its Parkinson's treatment, which is reputed to have gone exceptionally well in pre-clinical trials, and the last is for its LentiVector drug delivery system which is in demand from other pharmaceutical companies.

Thanks both. rayrac your post backs up my view. How many OXB peers can boast a potential product pipline like that?

Oxford BioMedica and its partner Viragen Inc announced reaching a further milestone in their avian transgenics cooperation, having successfully expressed interferon alpha-2a in white eggs laid by transgenic hens.

Alpha interferon is a protein produced by the human immune system that is fundamental to the body's resistance to disease.

This is the third therapeutic protein expressed thus far in a series of 'proof-of-principle' studies, which aim to develop the OVA System (Avian Transgenic Biomanufacturing) as a large-scale biomanufacturing alternative capable of cost-effectively expressing many types of therapeutic proteins.

This latest OVA-expression study produced interferon alpha-2a, which is the active ingredient in Roferon-A, a Roche Holdings AG drug approved for the treatment of certain chronic infectious diseases and cancers.

Without wanting to sound like a policeman can I just say: Hello, hello, what's going on here then? Through the 50p barrier like it wasn't even there. Is there an announcement imminent.....?

I HAVE SOLD /// THAT THE REASON/

What's the reason??

What's going on here, if I may be so bold as to answer your rhetorical question, is that a good stock with tremendous potential is finally being recognised and the share price is now roughly half it's value later this year, and a third of next.

Only danger I can see is if our friend says he loves it.

I hear from the other side that the rumour is Glaxosmithkline are gonna take them out for 70p...it was in one of the newspapers...I'll find it and post it...I'm still holding :-)
Di

Market Report: Oxford Biomedica (LSE: OXB.L - news) (rumours of a 70 pence-a-share bid approach, possibly from GlaxoSmithKline (LSE: GSK.L - news) )
Guardian

http://uk.biz.yahoo.com/070204/323/gy4eh.html

Financial Times
6/2/2007

Oxford BioMedica rose 12 per cent to 51p, its highest level for more than six years, amid continued speculation that GlaxoSmithKline would be unveiled as its partner to develop the cancer vaccine Trovax.

Sunday Times Business
Major Share Movements
11-2-2007

Oxford Biomedica. + 7.5p. Hopes of GSK tie-up.

ProActive Investor
Feb. 2007

Clearly there are a few takeover rumours doing the rounds, and in the case of this company, the rumours appear to have some justification as this company does have some exciting products in the pipeline and controls a new gene delivery platform - OXB should be tempting to a bigger fish.

http://www.proactiveinvestors.co.uk/articles/article.asp?OXB2

- yes, but at what price?
I can't see a Takeover being the solution.....IF these drugs are as good as they appear...( that's an IF, until proven.) then who would sell at 50p-ish? Clearly the value is linked to the size of the "market-share" profits likely over several years...discounted as time-line moves further away; so maybe over five, or six years after aprovals, which should start "soon" - therefore I suspect 50p-ish is the starting point with the likes of Glaxo wanting to be certain they aren't spending money the don't need to. Sure it means they will "pay more" but large Pharmas don't want to take a scatter-gun approach and buy "anything that moves".....they have their own research facilities for "speculative" products...and presumably they only go with the best (of those).
So it's still a waiting game IMHO - we have to be patient.
Ludlow castle (a fine piece of masonry overlooking the Shropshire plains), will have to bide his time. As will those of us who have been focussed on this gem (er, -to be proved)---- just that bit longer.
The signs are good and in my opinion, the longer OXB can hold-off a partnering deal the better. ( They have sufficient funds I understand, standing at many Millions) - I suspect Prof AK isn't about to do a cheap deal....and as long as the OXB-products appear to be good, or even better than what's about currently, there is hope we could see ......1+
Ah! - that would be good, so patience - we have seen a sea-change from 30p-ish at the start of the year to about 50p-ish now (ie in two months). The market should still be buying March/April (end of PEP/ISA year), then we could see a further rise, maybe half as much again - say 60p-ish.....but expect a fall-back to 50p-ish over the long summer.....(I assume no approval, although this could be "anytime")...
Approval will make the Market react IMHO and a 50% rise is not impossible, so that would put OXB on a new plateau between 75-90p depending upon the results and the "then-sp".....will it hit 1 this year?....I have my doubts on approval-alone...........a deal would be nice.......since OXB needs a partner that knows the US-market.....but with Approval AND Partner-deal it would seem an easy reach.....so let's hope-so.

Well, holding-it looks fine from here.
....DYOR, as always.....

Thanks hongon, interesting read.

Fair value on a world-wide deal for TroVax, or a take-over, would be more like 140p to 160p.

Be nice to see it up @ that value of approx 1.00. per share

news out ?

PARKIN, I reckon OXB are currently worth 140p to 160p.

TroVax could secure the Company one of the biggest partnering deals in the biotech sector so far, for example, at least $100m upfront and $800m in milestones, maybe more judging by some other recent deals (they just keep getting bigger and bigger, and for ever more early stage drugs).

cynic whats your views on this one how do the chart much up their allso news out today with some more news out on march 6th..........

FWIW: there are to be institutional presentations next week (see RNS), and you can view the web-cast - not the best of software interpretations, but it's sure better than catching the train.

Threrfore I expect some price rise, as MM's get better prices once institutions show willingness to buy.
[Of course, the sp must be seen in relation to the Market as a whole - - if we see further falls (blamed on China?), then expect OXB to be affected however slightly.]

I'm just hoping OXB continues to gather strength; it looks a long way from the 20p region of not so long ago. Perhaps we shall have some progress on the trials - that would be bound to affect the sp as we get closer to pay-back time.